Spyre Current Deferred Revenue vs Total Assets Analysis
| SYRE Stock | 27.00 0.50 1.82% |
Spyre Therapeutics financial indicator trend analysis is much more than just breaking down Spyre Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Spyre Therapeutics is a good investment. Please check the relationship between Spyre Therapeutics Current Deferred Revenue and its Total Assets accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.
Current Deferred Revenue vs Total Assets
Current Deferred Revenue vs Total Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Spyre Therapeutics Current Deferred Revenue account and Total Assets. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Spyre Therapeutics' Current Deferred Revenue and Total Assets is -0.01. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Total Assets in the same time period over historical financial statements of Spyre Therapeutics, assuming nothing else is changed. The correlation between historical values of Spyre Therapeutics' Current Deferred Revenue and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Spyre Therapeutics are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Current Deferred Revenue i.e., Spyre Therapeutics' Current Deferred Revenue and Total Assets go up and down completely randomly.
Correlation Coefficient | -0.01 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Total Assets
Total assets refers to the total amount of Spyre Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Spyre Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Most indicators from Spyre Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Spyre Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.At present, Spyre Therapeutics' Sales General And Administrative To Revenue is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 77.9 M, whereas Tax Provision is projected to grow to (24.7 K).
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 111K | 837K | 6.1M | 6.5M | Net Interest Income | 111K | 837K | 6.1M | 6.5M |
Spyre Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Spyre Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Spyre Therapeutics fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 83.2M | 161.6M | 109.9M | 71.1M | 341.9M | 359.0M | |
| Other Current Liab | 14.8M | 464K | 14.0M | 12.8M | 31.1M | 32.6M | |
| Total Current Liabilities | 18.4M | 16.4M | 20.1M | 14.7M | 32.0M | 16.7M | |
| Total Stockholder Equity | 60.1M | 139.8M | 83.9M | 50.3M | 184.0M | 96.1M | |
| Property Plant And Equipment Net | 1.0M | 7.2M | 9.9M | 8.4M | 6.7M | 0.0 | |
| Net Debt | (14.1M) | (84.6M) | (10.1M) | (30.2M) | (104.3M) | (99.1M) | |
| Retained Earnings | (195.1M) | (276.0M) | (341.8M) | (425.6M) | (764.4M) | (726.2M) | |
| Accounts Payable | 3.2M | 2.3M | 3.3M | 677K | 896K | 1.6M | |
| Cash | 19.3M | 90.1M | 15.1M | 34.9M | 188.9M | 198.3M | |
| Non Current Assets Total | 8.7M | 11.8M | 11.0M | 8.9M | 331K | 314.5K | |
| Non Currrent Assets Other | 11K | 115K | 842K | 683K | 9K | 8.6K | |
| Cash And Short Term Investments | 71.9M | 146.3M | 93.1M | 55.7M | 339.3M | 356.2M | |
| Net Receivables | 3.1M | 300K | 815K | 375K | 337.5K | 320.6K | |
| Common Stock Shares Outstanding | 1.3M | 2.1M | 2.6M | 3.4M | 6.9M | 7.2M | |
| Short Term Investments | 52.7M | 56.2M | 78.0M | 20.8M | 150.4M | 157.9M | |
| Liabilities And Stockholders Equity | 83.2M | 161.6M | 109.9M | 71.1M | 341.9M | 359.0M | |
| Non Current Liabilities Total | 4.7M | 5.3M | 5.8M | 6.2M | 125.9M | 132.2M | |
| Other Current Assets | 2.6M | 3.5M | 4.9M | 6.2M | 2.3M | 3.4M | |
| Other Stockholder Equity | 255.1M | 415.8M | 425.8M | 476.0M | 763.2M | 801.4M | |
| Total Liab | 23.1M | 21.8M | 26.0M | 20.8M | 157.8M | 165.7M | |
| Total Current Assets | 74.5M | 149.8M | 98.9M | 62.3M | 341.5M | 358.6M | |
| Accumulated Other Comprehensive Income | 51K | 11K | (20K) | (48K) | 302K | 317.1K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Spyre Therapeutics is a strong investment it is important to analyze Spyre Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Spyre Therapeutics' future performance. For an informed investment choice regarding Spyre Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spyre Therapeutics. If investors know Spyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (37.90) | Return On Assets (0.39) | Return On Equity (0.92) |
The market value of Spyre Therapeutics is measured differently than its book value, which is the value of Spyre that is recorded on the company's balance sheet. Investors also form their own opinion of Spyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spyre Therapeutics' market value can be influenced by many factors that don't directly affect Spyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.